A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback